申请人:University of Maryland
公开号:US05599959A1
公开(公告)日:1997-02-04
The present invention provides a salicylate analogue having the structure ##STR1## wherein R is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl; pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, phenyl, naphthyl and cyclohexyl; wherein R1 is selected from the group consisting of hydrogen, a C1-C12 alkyl group, F, Cl, Br, I, CO.sub.2 H, CONHR, CONR.sub.2, CO.sub.2 R, C.tbd.N, CHO, COR, SO.sub.3, SO.sub.2 NHR, SO.sub.2 NR.sub.2, OH, OR, OCOR, SH, SR, OCONHR, OCONR.sub.2, SCOR, SCONHR, SCONR.sub.2 and NH2, NHR, NHCOR and NR2; and wherein R1 is in the 3-, 4-, 5- or 6-position, or a combination thereof. Also provided are various pharmaceutical compositions of the novel compounds of the present invention.
本发明提供了一种水杨酸类似物,其结构为##STR1##其中R选自氢、甲基、乙基、正丙基、异丙基、正丁基、异丁基、戊基、己基、庚基、壬基、癸基、十一基、苯基、萘基和环己基等基团;其中R1选自氢、C1-C12烷基、F、Cl、Br、I、CO.sub.2 H、CONHR、CONR.sub.2、CO.sub.2 R、C.tbd.N、CHO、COR、SO.sub.3、SO.sub.2 NHR、SO.sub.2 NR.sub.2、OH、OR、OCOR、SH、SR、OCONHR、OCONR.sub.2、SCOR、SCONHR、SCONR.sub.2、NH2、NHR、NHCOR和NR2等基团;其中R1位于3-、4-、5-或6-位,或其组合位置。本发明还提供了各种新化合物的药物组合物。